Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
6(50.0%)
Phase 1
5(41.7%)
Phase 3
1(8.3%)
12Total
Phase 2(6)
Phase 1(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT05387785Phase 1Unknown

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

Role: lead

NCT04939116Phase 2Unknown

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Role: lead

NCT04196179Phase 1Completed

ANG-3070 in Healthy Adult Participants

Role: lead

NCT02771509Phase 2Unknown

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Role: lead

NCT04958187Phase 1Unknown

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

Role: lead

NCT04931524Phase 1Unknown

A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777

Role: lead

NCT02474667Phase 3Unknown

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

Role: lead

NCT04898907Phase 1Unknown

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

Role: lead

NCT04459676Phase 2Unknown

Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia

Role: lead

NCT01561599Phase 2Unknown

Study on Delayed Graft Function Using Paired Kidneys

Role: lead

NCT01286727Phase 2Unknown

Study to Improve Renal Function After Kidney Transplantation

Role: lead

NCT01539590Phase 2Terminated

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

Role: lead

All 12 trials loaded